0.5 mg + 0.4 mg (0.5 mg/0.4 mg), hard capsules
Dutasteride + Tamsulosin hydrochloride
Duodart is used in men with an enlarged prostate gland( benign prostatic hyperplasia) – a non-cancerous enlargement of the prostate gland caused by excessive production of a hormone called dihydrotestosterone.
The Duodart capsules are a combination of two other medicines: dutasteride and tamsulosin.
Dutasteride belongs to a group of medicines called 5-alpha-reductase inhibitors, and tamsulosin belongs to a group of medicines called alpha-adrenergic receptor antagonists.
An enlarged prostate gland can lead to problems with urination, such as difficulty urinating and frequent urination. There may also be a decrease in urine flow and a weak urine stream. If left untreated, it can lead to complete blockage of urine flow ( acute urinary retention). This situation requires immediate treatment. In some cases, surgery may be necessary to remove the prostate gland or reduce its size.
Dutasteride reduces the production of the hormone dihydrotestosterone, which leads to a reduction in the size of the prostate gland and alleviation of symptoms. By doing so, dutasteride reduces the risk of acute urinary retention and the need for surgical intervention. The action of tamsulosin involves relaxing the muscles in the prostate gland, making it easier to urinate and providing quick relief from symptoms.
(see section 6.),
Before starting treatment with Duodart, the patient should discuss it with their doctor.
In case of questions about taking Duodart, the patient should consult their doctor or pharmacist.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
The patient should not take Duodart with the following medicines:
It is not recommended to take Duodart with the following medicines:
The patient should inform their doctorif they are taking any of these medicines.
Duodart should be taken 30 minutes after the same meal every day.
Taking Duodart during pregnancy is contraindicated.
Dutasteride is absorbed through the skin and may disrupt the development of a male fetus. There is a particular risk during the first 16 weeks of pregnancy.
The patient should use a condom during sexual intercourse. Dutasteride has been found in the semen of men taking Duodart. If the partner is pregnant or may become pregnant, the patient should avoid exposing them to semen.
It has been shown that Duodart can reduce sperm count, semen volume, and sperm motility. This may lead to reduced fertility in men.
If a pregnant woman has come into contact with Duodart, she should consult her doctor.
In some patients, Duodart may cause dizziness, which may negatively affect the ability to drive or operate machinery.
If such symptoms occur, the patient should not drive or operate machinery.
Duodart contains a coloring agent – orange yellow S (E 110), which may cause allergic reactions.
Duodart contains soybean lecithin. It should not be taken in case of known hypersensitivity to peanuts or soy.
This medicine should always be taken as directed by the doctor or pharmacist. Irregular intake of the medicine may affect the results of PSA level tests. In case of doubts, the patient should consult their doctor or pharmacist.
The capsule should be swallowed whole with water. The capsules should not be chewed or opened.
Contact with the contents of the capsules may cause mouth or throat pain.
If more Duodart capsules than recommended are taken, the patient should consult their doctor or pharmacist.
The patient should not take a double dose to make up for a missed dose. They should take the next capsule at the usual time.
The patient should not stop taking Duodart unless their doctor recommends it.
In case of any further doubts about taking this medicine, the patient should consult their doctor or pharmacist.
Symptoms of an allergic reaction may include:
Duodart may cause dizziness or, in rare cases, fainting. Until it is known how the medicine affects the patient, they should be careful when changing positions from lying down or sitting to sitting or standing, especially when getting up at night. If dizziness occurs at any time during treatment, the patient should sit or lie down and wait for the symptoms to pass.
Symptoms of a serious skin reaction may include:
These may occur in up to 1 in 10 men taking Duodart:
These may occur in up to 1 in 100 men taking Duodart:
These may occur in up to 1 in 1000 men taking Duodart:
These may occur in up to 1 in 10,000 men taking Duodart:
Other side effects have occurred in a small number of men, but their exact frequency is unknown (based on available data, the frequency cannot be estimated):
If the patient experiences any side effects, including any not listed in the leaflet, they should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety, Ministry of Health, via phone: +48 22 49 21 301, fax: +48 22 49 21 309, or website: https://smz.ezdrowie.gov.pl.
By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
The patient should not take this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
The medicine should not be stored above 30°C.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer need. This will help protect the environment.
The active substances of Duodart are dutasteride and tamsulosin hydrochloride. Each capsule contains 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride.
Soft capsule with dutasteride: mono-di-glycerides of caprylic/capric acid, butylhydroxytoluene (E 321); soft capsule shell:gelatin, glycerol, titanium dioxide (E 171), yellow iron oxide (E 172), medium-chain triglycerides, lecithin (may contain soybean oil).
Pellets with tamsulosin hydrochloride: microcrystalline cellulose, methacrylic acid-ethyl acrylate copolymer (1:1) dispersion 30% (contains polysorbate 80 and sodium lauryl sulfate), talc, triethyl citrate.
Hard capsule shell:carrageenan (E 407), potassium chloride, red iron oxide (E 172), titanium dioxide (E 171), hypromellose, carnauba wax, cornstarch, orange yellow S (E 110)
black ink SW-9010:shellac, propylene glycol, black iron oxide (E 172)
or black ink SW-9008: shellac, propylene glycol, black iron oxide (E 172), potassium hydroxide.
Duodart is a hard capsule with a brown body and an orange cap, with a black ink print. Duodart is available in packs of 30 capsules.
For more detailed information, the patient should consult the marketing authorization holder or parallel importer.
GlaxoSmithKline, S.A.
P.T.M. C/Severo Ochoa, 2
28760 Tres Cantos (Madrid)
Spain
Catalent Germany Schorndorf GmbH
Steinbeisstrasse 2
73614 Schorndorf
Germany
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in Spain, the country of export:700698.5
Duodart -Austria, Bulgaria, Cyprus, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Iceland, Italy, Latvia, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain
Combodart -Belgium, Estonia, France, Ireland, Lithuania, Luxembourg, Malta, Slovenia, United Kingdom
Date of leaflet approval: 20.05.2022
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.